Pegenzileukin
- Generic Name
- Pegenzileukin
- Drug Type
- Biotech
- CAS Number
- 2573074-47-0
- Unique Ingredient Identifier
- 10WR240QN7
Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma
- Conditions
- Oropharynx CancerHead and Neck CancerSquamous Cell Carcinoma
- Interventions
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05535023
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]
- Conditions
- Classic Hodgkin LymphomaDiffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 14
- Registration Number
- NCT05179603
- Locations
- 🇨🇱
Investigational Site Number : 1520002, Santiago, Reg Metropolitana De Santiago, Chile
🇨🇱Investigational Site Number : 1520004, Vina del Mar, Valparaíso, Chile
🇨🇱Investigational Site Number : 1520001, Temuco, Chile
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
- Conditions
- Oesophageal Squamous Cell CarcinomaColorectal CancerOesophageal AdenocarcinomaGastric CancerHepatocellular Carcinoma
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 138
- Registration Number
- NCT05104567
- Locations
- 🇺🇸
Seattle Cancer Care Alliance Site Number : 8400009, Seattle, Washington, United States
🇳🇱Investigational Site Number : 5280001, Amsterdam, Netherlands
🇮🇹Investigational Site Number : 3800003, Milano, Italy
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
- Conditions
- Pleural MesotheliomaNon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 106
- Registration Number
- NCT04914897
- Locations
- 🇮🇹
Investigational Site Number : 3800005, Aviano (PN), Friuli-Venezia Giulia, Italy
🇮🇹Investigational Site Number : 3800001, Rozzano, Milano, Italy
🇰🇷Investigational Site Number : 4100001, Seoul, Seoul-teukbyeolsi, Korea, Republic of
A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)
- Conditions
- Malignant MelanomaSquamous Cell Carcinoma of Skin
- Interventions
- First Posted Date
- 2021-06-04
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 46
- Registration Number
- NCT04913220
- Locations
- 🇫🇷
Investigational Site Number : 2500003, Bobigny, France
🇨🇱Investigational Site Number : 1520006, Antofagasta, Chile
🇦🇺Investigational Site Number : 0360001, Macquarie University, New South Wales, Australia
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
- Conditions
- Plasma Cell Myeloma Refractory
- Interventions
- First Posted Date
- 2020-11-24
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 197
- Registration Number
- NCT04643002
- Locations
- 🇰🇷
Investigational Site Number : 4100002, Seoul, Korea, Republic of
🇺🇸University of Illinois at Chicago- Site Number : 8400007, Chicago, Illinois, United States
🇺🇸University of Michigan Health System - Ann Arbor- Site Number : 8400004, Ann Arbor, Michigan, United States
A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)
- Conditions
- Metastasis
- Interventions
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Synthorx, Inc, a Sanofi company
- Target Recruit Count
- 250
- Registration Number
- NCT04009681
- Locations
- 🇦🇺
Investigational Site Number-2002, Victoria, Australia
🇦🇺Investigational Site Number-2003, Victoria, Australia
🇨🇱Investigational Site Number- 6001, Santiago, Chile
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.